22:40 , Jun 19, 2017 |  BC Extra  |  Clinical News

Antibiotic derived from soil could address drug resistance

In a paper published in Cell, researchers described a nucleoside analog antibiotic derived from soil microbes that inhibits bacterial RNA polymerase (RNAP). The team said the compound, pseudouridimycin, showed broad effectiveness against a range of...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, international Phase III TARGET 3 trial in 636 patients with IBS-D showed that retreatment with thrice-daily 550 mg oral Xifaxan met the secondary composite endpoint of a greater proportion of...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Phase III data

The double-blind, international Phase III TARGET 3 trial in about 800 patients with IBS-D showed that retreatment with thrice-daily 550 mg oral Xifaxan for 2 weeks met the composite primary endpoint of a greater proportion...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Bacterial RNA polymerase (RNAP) In vitro studies identified bivalent inhibitors of RNAP that could...
07:00 , May 22, 2014 |  BC Innovations  |  Strategy

Antibiotic team building

The National Institute of Allergy and Infectious Diseases has awarded a 5-year, $26 million grant to a center for antibiotic development that brings together researchers from Rutgers University, The Rockefeller University and Cubist Pharmaceuticals Inc....
08:00 , Dec 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Bacterial RNA polymerase Computational and SAR studies suggest anthranilic...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Rifaximin soluble solid dispersion: Phase II started

Salix disclosed in its 2Q13 earnings that in June it began a double-blind, U.S. Phase II trial to evaluate once-daily rifaximin SSD tablets for 24 weeks in about 420 patients. Patients will receive 40 or...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Phase III started

Salix began the U.S. Phase III Target 3 trial to evaluate retreatment with 550 mg oral Xifaxan given thrice daily for 2 weeks in about 800 patients with IBS-D. Following a run-in period with placebo,...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, North American Phase III TARGET 1 trial in 600 patients showed that 41% of patients treated with 550 mg oral Xifaxan thrice daily for 14 days achieved adequate relief of...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Xifaxan rifaximin: Additional Phase III data

Additional data from the double-blind, North American Phase III TARGET 2 trial in 600 patients showed that 41% of patients treated with 550 mg oral Xifaxan thrice daily for 14 days achieved adequate relief of...